Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer
Cancer, 04/19/2012
Clinical Article
Arvold ND et al. – Gemcitabine–based neoadjuvant chemotherapy confers a significant OS advantage by allowing the selection of patients who will derive greatest benefit from chemoradiation therapy (CRT). Median survival with this approach was similar to that seen with surgical resection.



